PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9900952-4

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/44, 31/415

A1

(11) International Publication Number: WO 98/16228

(43) International Publication Date: 23 April 1998 (23.04.98)

(21) International Application Number: PCT/SE97/01651

(22) International Filing Date: 1 October 1997 (01.10.97)

(30) Priority Data:
9603725-4 11 October 1996 (11.10.96) SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG (publ) [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: LINDBERG, Per [SE/SE]; Gundas Gata 40, S-431 51 Mölndal (SE). PINAS-MASSO, Joan [ES/ES]; 2°-3° piso, Placa Francesc Masia, 8, E-08029 Barcelona (ES). SERRA-CARRERAS, Jordi [ES/ES]; 1°-3° piso, Paseo Pere III, 71ü, E-08240 Manresa (ES). TRO-FAST, Jan [SE/SE]; Vapenkroken 34, S-226 47 Lund (SE).

(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF AN H^+, K^+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS

(57) Abstract

The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H^+, K^+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the treatment of asthma.